KalVista Pharmaceuticals (KALV)
(Delayed Data from NSDQ)
$11.78 USD
-0.27 (-2.24%)
Updated Jun 28, 2024 04:00 PM ET
After-Market: $11.75 -0.03 (-0.25%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum D VGM
Brokerage Reports
KalVista Pharmaceuticals, Inc. [KALV]
Reports for Purchase
Showing records 81 - 100 ( 106 total )
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
FY1Q Update - With Two Shots on Goal by YE2019, We''re Liking Our Odds
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Pullback in KALV Creates a Buying Opportunity. Reiterate Buy and $30 PT.
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Invitation to Join Kalvista''s Management Call '-' August 19th as 12pm (ET)
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
FY2019 Update Highlights Several Near-Term, Value-Driving Catalysts
Provider: Roth Capital Partners, Inc.
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Board Chair Change Comes Ahead of Major Data Readouts in 2H19. Buy $30 PT
Provider: Roth Capital Partners, Inc.
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Transfer of Coverage; Maintain Buy Rating and $30PT
Provider: Roth Capital Partners, Inc.
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
California Dreamin? I: Biotech Stories To Keep An Eye On
Provider: Roth Capital Partners, Inc.
Analyst: MARANGO J
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
HAE Program Marches On; Maintain Buy - Raising PT to $25
Provider: Roth Capital Partners, Inc.
Analyst: MARANGO J
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: KalVista Pharmaceuticals, Inc.
Industry: Medical - Drugs
First HAE Candidate Unveiled; Reiterate Buy - Raising PT to $22
Provider: Roth Capital Partners, Inc.
Analyst: MARANGO J